Quoin Pharmaceuticals, Ltd. American Depositary Shares (QNRX)

Quoin Pharmaceuticals reported a net loss of $6.28 per share in Q2 2025, which exceeded analyst estimates. The company is developing QRX003, a topical lotion for Netherton Syndrome, and made significant clinical and regulatory progress while increasing R&D spending.

Quoin Pharmaceuticals announced highly positive interim data from its ongoing Netherton Syndrome clinical trials, with the first subject demonstrating marked improvements across all measured endpoints after 12 weeks of treatment with the company's QRX003 topical lotion. The company is optimistic about the therapy's potential to effectively treat this rare and debilitating skin disease.

Maxim Group has decided to maintain its Buy rating of Quoin Pharmaceuticals (NASDAQ:QNRX) and lower its price target from $15.00 to $4.00. Shares of Quoin Pharmaceuticals are trading up 2.0% over the last 24 hours, at $1.02 per share. A move to $4.00 would account for a 292.16% increase from the current share price. About Quoin Pharmaceuticals Quoin Pharmaceuticals Ltd is a pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of ...Full story available on Benzinga.com

Penny stocks to buy according to analysts in 2022. The post 7 Penny Stocks To Buy According To Top Wall Street Analysts appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Endo's (ENDP) subsidiary, Endo Ventures, signs agreement with Quoin Pharmaceuticals for developing/commercializing the latter's pipeline candidate, QRX003, for treating Netherton syndrome in Canada.